FDA Drug Recalls

Recalls / Class II

Class IID-0564-2024

Product

Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit with Luer Lock, For Intramuscular or Intravenous Use, Rx Only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA. NDC: 0409-2012-03

Brand name
Buprenorphine Hydrochloride
Generic name
Buprenorphine Hydrochloride
Active ingredient
Buprenorphine Hydrochloride
Route
Intramuscular, Intravenous
NDC
0409-2012
FDA application
ANDA074137
Affected lot / code info
Lot#: HJ3965; Exp 2024/09 Lot#: HJ8546; Exp 2024/10

Why it was recalled

Lack of Assurance of Sterility-The potential for incomplete crimp seals.

Recalling firm

Firm
Pfizer Inc.
Manufacturer
Hospira, Inc.
Notification channel
Letter
Type
Voluntary: Firm initiated
Address
235 East 42nd Street, New York, New York 10017-5703

Distribution

Quantity
84,710 cartridges
Distribution pattern
US Nationwide and Puerto Rico.

Timeline

Recall initiated
2024-05-20
FDA classified
2024-06-22
Posted by FDA
2024-07-03
Status
Ongoing

Source: openFDA Drug Enforcement endpoint. Recall record D-0564-2024. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.